Puma Biotechnology (PBYI) Cost of Revenue (2017 - 2026)
Puma Biotechnology's (PBYI) quarterly Cost of Revenue came in at $10.4 million in Q1 2026, down 1.25% YoY from $10.6 million in Q1 2025, and down 54.93% on a QoQ basis from $23.1 million in Q4 2025.
Puma Biotechnology (PBYI) Cost of Revenue (2017 - 2026) Analysis & Trends
Puma Biotechnology (PBYI) has 10 years of Cost of Revenue data on file, last reported at $10.4 million in Q1 2026.
- Quarterly Cost of Revenue fell 1.25% year-over-year to $10.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $58.0 million (down 9.66% YoY) and the FY2025 annual result came in at $58.2 million, down 9.7% from the prior year.
- Cost of Revenue retreated to $10.4 million in Q1 2026, from $23.1 million in the prior quarter.
- In the past five years, Cost of Revenue ranged from a high of $29.1 million in Q3 2024 to a low of $10.4 million in Q1 2026.
- A 5-year average of $14.8 million and a median of $12.5 million in 2022 frame the typical range for Cost of Revenue.
- Annual changes were most pronounced in 2022 — Cost of Revenue plunged 63.31% — and 2024, when it surged 119.04%.
- Tracing PBYI's Cost of Revenue over 5 years: stood at $16.8 million in 2022, then surged by 44.47% to $24.3 million in 2023, then plunged by 42.77% to $13.9 million in 2024, then soared by 66.13% to $23.1 million in 2025, then sank by 54.93% to $10.4 million in 2026.
- The last three Cost of Revenue figures came in at $10.4 million (Q1 2026), $23.1 million (Q4 2025), and $12.2 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cost of Rev (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 489.20 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 360.70 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 145.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 174.53 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 1.18 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 298.26 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 67.21 Mn |
| 10 | Puma Biotechnology | 451.24 Mn | 357.33 Mn | 44.03 Mn | 12.48 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 12.48 Mn |
| Jun 30, 2026 | 12.48 Mn |
| Mar 31, 2026 | 10.42 Mn |
| Mar 31, 2026 | 10.42 Mn |
| Dec 31, 2025 | 23.13 Mn |
| Dec 31, 2025 | 23.13 Mn |
| Sep 30, 2025 | 12.17 Mn |
| Sep 30, 2025 | 12.17 Mn |
| Jun 30, 2025 | 12.30 Mn |
| Jun 30, 2025 | 12.30 Mn |
| Mar 31, 2025 | 10.56 Mn |
| Mar 31, 2025 | 10.56 Mn |
| Dec 31, 2024 | 13.92 Mn |
| Dec 31, 2024 | 13.92 Mn |
| Sep 30, 2024 | 29.10 Mn |
| Sep 30, 2024 | 29.10 Mn |
| Jun 30, 2024 | 10.66 Mn |
| Jun 30, 2024 | 10.66 Mn |
| Mar 31, 2024 | 10.73 Mn |
| Mar 31, 2024 | 10.73 Mn |